Autoantibodies as biomarkers;Les auto-anticorps comme biomarqueurs

Presse Medicale

Volumn 43, Issue 1, 2014, Pages 57-65

  Tron, François ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER;

ANTIBODY PRODUCTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CLINICAL FEATURE; HUMAN; PREDICTION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 84892476970     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.11.025     Document Type: Short Survey

References (31)

1. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies are present years before the clinical onset of systemic lupus erythematosus. N Eng J Med 2003, 349:1526-1533.
2. Bingley P.J., Bonifacio E., Williams A.J., Genovese S., Bottazzo G.F., Gale E.A. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997, 46:1701-1710.
3. Nell V.P.K., Machold K.M., Stamm T.A., Eberl G., Heinzl H., Saloojee N., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005, 64:1731-1736.
4. Wener H.M. Laboratory tests for autoimmune rheumatology disorders. Educational review manual in rheumatology 2007, 1-42. Castle Connolly Graduate Medical Publishing Ltd, New York. 4th ed.
5. Wang J., Satoh M., Kabir F., Shaw M., Domingo M.A., Mansoor R., et al. Increased prevalence of autoantibodies to Ku antigen in African Americans versus Caucasians with systemic lupus erythematosus. Arthritis Rheum 2001, 44:2367-2370.
6. Ishibashi H., Shimoda S., Gershwin M.E. The immune response to mitochondrial autoantigens. Sem Liver Dis 2005, 25:337-346.
7. Strassburg C.P., Manns M. Liver cytosol antigen type I autoantibodies, liver kidney microsomal autoantibodies and liver microsomal autoantibodies. Autoantibodies 2007, 463-471. Elsevier, Amsterdam. 2e ed. M.E. Shoenfeld, Y. Gershwin, P.L. Meroni (Eds.).
8. Mouquet H., Gilbert D., Musette P., Tron F., Joly P. Molecular advances in pathogenesis of autoimmune blistering skin diseases. Ann Dermatol Venereol 2005, 132:231-242.
9. Rostom A., Dubé C., Cranney A., Saloojee N., Sy R., Garritty C., et al. The diagnostic accuracy of serological tests for celiac disease: a systematic review. Gastroenterology 2005, 128:S38-S46.
10. Turner R., Stratton I., Horton V., Manley S., Zimmet P., Mackay I.R., et al. UKPDS 25: autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997, 350:1288-1293. [Erratum in: Lancet 1998;351(9099):376].
11. Betterle C., Dal Pra C., Mantero F., Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens and their application in diagnosis and disease prediction. Endocr Rev 2002, 23:327-364.
12. Sacré K., Lidove O., Chanson N., Laganier J., Vidailhet M., Lejoyeux M., et al. Acute psychosis in anti-nMDA receptor encephalitis. Presse Med 2011, 40:882-884.
13. Targoff I.N. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:859-890.
14. Möttönen T., Paimela L., Leirisalo-Repo M., Kautiainen H., Ilonen J., Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with sawtooth strategy. Ann Rheum Dis 1998, 57:533-539.
15. van Venrooij W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011, 7:391-398.
16. Le Loët X., Brazier M., Mejjad O., Boumier P., Daragon A., Gayet A., et al. Serum IgA rheumatoid factor and pyridoline in very early arthritis are predictors of erosion at 2 years; a simple model of prediction from a conservately treated community based inception cohort. Arthritis Care Res 2010, 62:1739-1747.
17. Li N., Aoki V., Hans-Filho G., Rivitti E.A., Diaz L.A. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med 2003, 197:1501-1510.
18. Rigopoulou E.I., Davies E.T., Pares A., Zachou K., Liaskos C., Bogdanos D.P., et al. Prevalence and clinical significance of isotype specific anti-nuclear antibodies in primary biliary cirrhosis. Gut 2005, 54:528-532.
19. Sokolove J., Bromberg R., Deane K.D., Lahey L.J., Derber L.A., Chandra P.E., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression in rheumatoid arthritis. PloS One 2012, 7:e35295.
20. Seissler J., Morgenthaler N.G., Achenbach P., Lampeter E.F., Glawe D., Payton M., et al. Combined screening for antibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. Deutsche Nikotinamid Interventions-studie. Diabetologia 1996, 39:1351-1356.
21. Kulmala P., Savola K., Petersen J.S., Vähäsalo P., Karjalainen J., Löppönen T., et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. J Clin Invest 1998, 101:327-336.
22. Kupila A., Muona P., Simell T., Arvilommi P., Savolainen H., Hämäläinen A.M., et al. Juvenile diabetes research foundation centre for the prevention of type I diabetes in Finland. Feasability of genetic and immunological prediction of type I diabetes in a population-based birth control. Diabetologia 2001, 44:290-297.
23. Vanderpump M.P., Tunbridge W.M., French J.M., Appleton D., Bates D., Clark F., et al. The incidence of thyroid disorders in the community: a twenty years follow-up of the Whickham Survey. Clin Endocrinol 1995, 43:55-68.
24. Kita M., Coulis G.D., Avramides A. A postpartum thyroiditis in a mediterranean population. J Endocrinol Invest 2002, 25:513-519.
25. Johnston S.D., Watson R.G., Mcmillan S.A., Evans A.E., Love A.H. Serological markers for coeliac disease: changes with time and relationship to enteropathy. Eur J Gastroenterol Hepatol 1998, 10:259-264.
26. Nielen M.M., van Shaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386.
27. Roberts W.K., Darnell R.B. Neuroimmunology of the paraneoplastic neurological degeneration. Curr Opin Immunol 2004, 16:612-622.
28. Dörner T., Kinnman N., Tak P.P., Targeting B. cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010, 125:464-475.
29. Lal P., Su Z., Holweg C.T., Silverman G.J., Schwartzman S., Kelman A., et al. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following Rituximab treatment. Arthritis Rheum 2011, 63:3681-3691.
30. Emery P., Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011, 70:2063-2070.
31. Alessandri C., Scrivo R., Spinelli F.R., Ceccarelli F., Magrini L., Priori R., et al. Autoantibody production in anti-TNF-alpha-treated patients. Ann N Y Acad Sci 2007, 1110:319-329.